Falcon Point Capital’s Travere Therapeutics TVTX Stock Holding History

Falcon Point Capital’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-78,101	Closed	-$1.77M	–	109
2019 Q1	$1.77M	Sell	78,101 -2,277	-3%	-$50.3K	0.96%	43
2018 Q4	$1.82M	Sell	80,378 -89,146	-53%	-$2.22M	1.09%	41
2018 Q3	$4.87M	Buy	169,524 +32,148	+23%	+$919K	1.05%	45
2018 Q2	$3.75M	Buy	+137,376	New	+$3.66M	0.74%	49

Other funds holding TVTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Falcon Point Capital's TVTX Position: Q2 2019 in Review

Falcon Point Capital sold out of Travere Therapeutics (TVTX) in Q2 2019, closing a stake of 78,101 shares — an estimated $1.77M sold.

Falcon Point Capital first reported a position in TVTX in Q2 2018 and held it in 4 quarters. The position peaked at $4.87M in Q3 2018. 122 funds tracked by Wall St. Rank hold TVTX as of Q2 2019.

Falcon Point Capital reported no remaining Travere Therapeutics position as of Q2 2019 after selling out during the quarter.
Falcon Point Capital sold 78,101 Travere Therapeutics shares in Q2 2019, an estimated $1.77M.
Falcon Point Capital first reported a position in Travere Therapeutics in Q2 2018 and held it in 4 quarters.
Falcon Point Capital's Travere Therapeutics position peaked at $4.87M in Q3 2018.
122 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2019.

Based on Falcon Point Capital's 13F filing for Q2 2019, filed 15 Jul 2019.